Mirati Therapeutics, Inc.(NASDAQ : MRTX)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|SNSS||Sunesis Pharmaceuticals, Inc.||-7.57%||6.47||0.7%||$452.28m|
|GILD||Gilead Sciences, Inc.||-0.76%||67.63||1.0%||$426.45m|
|REGN||Regeneron Pharmaceuticals, Inc.||-0.43%||553.24||2.7%||$408.99m|
|XLRN||Acceleron Pharma, Inc.||0.50%||172.94||5.3%||$345.45m|
|VRTX||Vertex Pharmaceuticals, Inc.||-0.07%||181.77||1.9%||$259.59m|
|XENE||Xenon Pharmaceuticals, Inc.||2.12%||33.66||0.4%||$178.19m|
|JSPR||Jasper Therapeutics, Inc.||31.57%||16.42||0.0%||$158.53m|
Mirati Therapeutics, Inc. operates as a clinical-stage oncology company, which engages in the development of novel therapeutics. The firm's products targets the genetic and immunological promoters of cancer. Its clinical pipeline consists of Adagrasib, MRTX1133, and Sitravatinib. The company was founded on December 13, 1995 and is headquartered in San Diego, CA.